Subscribe to the gold package and get unlimited access to Shamra Academy
Register a new userThe Incidence of increased intraocular pressure ( I.O.P)after subtenon injection of triamcinolone acetonide
ارتفاع الضغط داخل المقلة (I. O .P) بعد حقن التريامسينولون اسيتونيد تحت التينون
1759
0 41
0
(
0
)
Authors
حبيب يوسف( باحث )
Created by
Shamra Editor
Ask ChatGPT about the research
الهدف: دراسة حدوث ارتفاع I.O.P بعد حقن تريامسينولون تحت التينون الطرق : تمت الدراسة على 40 مريض 50 عيناً تلقوا 40 مغ تريامسينولون تحت التينون لعلاج أمراض مختلفة تمت مراقبة الضغط داخل المقلة و تحديد العيون التي ارتفع فيها الضغط ≥ 5 ملمز و ذروة I.O.P و العلاقة بين I.O.P و العمر و الجنس و نوع المرض وعدد الحقن النتائج : I.O.P ≥ 5 ملمز وجد في 25 عيناً أي 50% من العيون المدروسة بدأ ارتفاع I.O.P بشكل هام بعد شهر من الحقن( 20% ) وصل إلى الذروة بعد 3 أشهر ( 80 % ) و عاد إلى المستوى الأساسي قبل الحقن بعد 10 أشهر يزداد I.O.P عند الشباب 80 % بالأعمار بين 40– 50 سنة وعند الإناث >الذكور ( 59,09% و 42,8%) على التوالي, وبالحقنة الوحيدة أقل من الحقن المتعددة ( 47,3% و 60%)على التوالي لا يوجد علاقة هامة بين نوع المرض المعالج و حقن التريامسينولون تحت التينون الاستنتاج: تعدد الحقن و الأعمار الشابة و خصوصاً بين النساء يزيد نسبة حدوث ارتفاع I.O.P بعد حقن التريامسينولون تحت التينون.
Purpose : to determine the incidence of eyes that have an increase in the intraocular pressure( I.O.P ) after subtenon injection of triamcinolone acetonide . Methods: 40 patient 50 eyes treated with 40 mg subtenon injection of TA for different diseases. The incidence of an I.O.P elevation ≥ 5mmhg was determine, the peak of I.O.P, the relation between I.O.P elevation and the age, gender, the kind of disease and the number of we injections of ta Results : an elevation I.O.P≥ 5mmhg was found in 25 eyes ( 50%) . The I.O.P began to increase significantly from 1 month (20%) The peak of I.O.P after 3 months (80%) and returned to the baseline I.O.P in 10 months . the elevation I.O.P≥ 5 mmhg was significantly related with younger age (80%) between 40-50 years the elevation I.O.P is between females' more in cedence than males (59,59%) females and (42,8%) males, and is less incidence aftere single injection (42.8%) less than multi injection (60%) multiple No significant relation is round between the disease and the incidence of increased I.O.P . Conclusion : repeated injections of TA and injection of younger patients especially women increase the incidence of an I.O.P elevation .
Artificial intelligence review:
Research summary
تهدف هذه الدراسة إلى تحديد نسبة حدوث ارتفاع ضغط العين (I.O.P) بعد حقن التريامسينولون تحت التينون. شملت الدراسة 40 مريضًا (50 عينًا) تلقوا 40 ملغ من التريامسينولون لعلاج أمراض مختلفة. تم قياس الضغط داخل العين على فترات زمنية مختلفة لتحديد العيون التي ارتفع فيها الضغط بمقدار ≥ 5 ملمز، وتحديد العلاقة بين ارتفاع الضغط والعمر والجنس ونوع المرض وعدد الحقن. أظهرت النتائج أن 50% من العيون المدروسة شهدت ارتفاعًا في الضغط بمقدار ≥ 5 ملمز، وبدأ الارتفاع بشكل ملحوظ بعد شهر من الحقن (20%) ووصل إلى الذروة بعد 3 أشهر (80%)، وعاد إلى المستوى الأساسي بعد 10 أشهر. كان الارتفاع أكثر شيوعًا بين الفئات العمرية الشابة (40-50 سنة) وبين النساء (59.09% مقابل 42.8% للرجال). كما أن الحقن المتعددة زادت من نسبة الارتفاع مقارنة بالحقن الوحيدة. لم تكن هناك علاقة هامة بين نوع المرض المعالج وارتفاع الضغط بعد الحقن. خلصت الدراسة إلى أن تكرار الحقن والأعمار الشابة، خصوصًا بين النساء، يزيد من نسبة حدوث ارتفاع الضغط بعد حقن التريامسينولون تحت التينون.
Critical review
تعتبر هذه الدراسة مهمة لأنها تسلط الضوء على تأثيرات جانبية هامة لحقن التريامسينولون تحت التينون، وهي ارتفاع ضغط العين. ومع ذلك، هناك بعض النقاط التي يمكن تحسينها. أولاً، كان من الأفضل تضمين مجموعة ضابطة لمقارنة النتائج وتحديد مدى تأثير التريامسينولون بشكل دقيق. ثانيًا، لم يتم توضيح كيفية اختيار المرضى وما إذا كانت هناك أي معايير استبعاد، مما قد يؤثر على تعميم النتائج. ثالثًا، كان من الممكن تقديم تحليل أكثر تفصيلاً للعوامل الأخرى التي قد تؤثر على ارتفاع الضغط مثل التاريخ الطبي للمرضى واستخدام أدوية أخرى. على الرغم من هذه النقاط، تقدم الدراسة بيانات قيمة يمكن أن تكون مفيدة للأطباء في اتخاذ قرارات علاجية مستنيرة.
Questions related to the research
-
ما هي نسبة العيون التي شهدت ارتفاعًا في ضغط العين بعد حقن التريامسينولون تحت التينون؟
50% من العيون المدروسة شهدت ارتفاعًا في الضغط بمقدار ≥ 5 ملمز.
-
متى يصل ارتفاع ضغط العين إلى الذروة بعد حقن التريامسينولون؟
يصل ارتفاع ضغط العين إلى الذروة بعد 3 أشهر من الحقن بنسبة 80%.
-
هل هناك علاقة بين ارتفاع ضغط العين والجنس؟
نعم، الارتفاع في ضغط العين كان أكثر شيوعًا بين النساء بنسبة 59.09% مقارنة بالرجال بنسبة 42.8%.
-
ما هي التوصيات التي قدمتها الدراسة بشأن استخدام التريامسينولون تحت التينون؟
توصي الدراسة بالحذر في استخدام التريامسينولون تحت التينون، خصوصًا في الأعمار الصغيرة وعند النساء، وتجنب تكرار الحقن قدر الإمكان، ومراقبة ضغط العين بشكل دوري بعد الحقن.
References used
yumikoyamamoto, md, tsutomukomatsu, mdyujikoura, mdkojinishino, md, phdatsukifukushimamd, phd, hisayukiueno , md. Intraocular pressure elevation after ibtravitreal or posterior sub tenon triamcinolone acetonide injection Canadian journal of ophthalmology volume 43,issue 1 February 2008 ,p 42-47, sciencedirect
sophiebakri md peter k Kaiser ,md, posterior subtenon triamcinolone acetonide for refractory diabetic macular edema American journal of ophthalmology volume 139,issue 2 february 2005,p 290-294
Ryosuke kawamura.makoto. hajimeshinoda. keishinoda . yujiitoh. susumuishida. Incidence of increased intraocular pressure after subtenon injection of triamcinolone acetonide , Americen Journal of gohthalmalogy,juni2011(3);299-304
rate research
Read More
The aim of this clinical study was to investigate the intraocular pressure (IOP) reduction after selective laser trabeculoplasty (SLT) in patients with primary open-angle glaucoma (POAG). The research has been done in Alassad Hospital, Tishreen unive
rsity, Lattakia, from Feb 2009 to Feb 2011. Fifty eyes with uncontrolled POAG were treated with a frequency doubled, Q-switched Nd:YAG laser (532 nm).The pattern of treatment was applying approximately 50 burns to 180 degrees of the trabecular meshwork at energy levels ranging from 0.40– 0.92 mJ per pulse. After SLT eyes were maintained with the identical hypotensive medical therapy as that before treatment. IOP was measured before treatment, 1 and 7 days after treatment and 1, 3, 6 and 12 months after treatment. The mean pretreatment IOP was 22.48 (SD 1.84) mmHg. At the end of 1 month follow-up period the mean reduction of IOP was 4.86 mmHg (21.6%); after 3 months the mean reduction was 5.66 mmHg (25.2%); after 6 months the mean reduction of IOP was 5.06 mmHg (22.5%); at the end of 12 months follow-up period the mean reduction was 4.92 mmHg (21.9%). It can be concluded that SLT presents a new and effective method of IOP reduction in the treatment of POAG.
In this study 500 obese pregnant women and 250 non-obese pregnant women
(Group of Control) were followed up to prove the role of obesity as a high risk
factor on the incidence of (P.I.H.). We found that:
1. There is a considerable increase in the
incidence of (P.I.H.), which was
proportional to the grade of obesity in the main group. The incidence of P.I.H.
was : %15.38 in grade 1, %26.42 in grade 2 and %42.22 in grade 3 of obesity
(Vs. %6.4 in the control group).
2. There is a considerable increase in the incidence of (P.I.H.) among the obese
pregnant women, especially when they are 36-45 years old (%32.39 Vs. %6.45
in control group).
So that it is advisable to screen all obese pregnant women especially when they
are 36-45 years old and consider them as a high risk group for the indicence of
(P.I.H.).
The study aims to investigate the efficacy of subcutaneous Betamethasone phosphate sodium injection in the treatment of chalazion. The research was carried out in Al-Assad Hospital, Tishreen University, Lattakia, in the period from January 2009 to De
cember 2010.
The study included 30 patients; their age ranged between 1-54 years. The patients had chalazion treated with an injection (0.2ml) of Betamethasone phosphate sodium in the subcutaneous tissue around the lesion. All injections were given by a single ophthalmologist. No local or topical anaesthetic was used. The patients were monitored after 2 weeks. The injection (half of the first dose 0.1ml) was repeated when the chalazion did not reduce, with a maximum of two more injections given over a 2-week interval.
Thirty patients with chalazion were followed up and treated with injection of Betamethasone phosphate sodium into the subcutaneous tissue around the lesion. In 27 patients (90%), the lesion subsided completely. 16 patients (53.3%) had lesions that subsided with one injection. 11 patients (36.7%) had lesions that subsided after the second injection. 3 patients (10%) did not respond to the treatment. The size and duration of the chalazion up till the time of the patients’ visit to the clinic did not significantly affect the outcome of the treatment. Two patients developed depigmentation of the skin at the site of injection. No other major complications were encountered.
Subcutaneous injection of the Betamethasone phosphate sodium appears to be a simple and effective treatment for chalazion. Further comparative clinical cases are indicated
The study was performed in 64 children aged 6 months to 5 years had
ventricuLar septal defect. Systolic pressure in the right ventricle and
Pulmonary Hypertension were determined by two ways.
1- From arteriovenous shunt via ventricular septal defe
ct the
correlation ratio of doppler echo cardiographic catheterization
values was %76.
2- From systolic regurgitation via the tricuspid valve the correlation
was %97.
Objective: Keloid pose aesthetic and functional problems, in addition to being associated with disturbing clinical symptoms such as itching and pain, and current methods of treatment are limited in effectiveness. Clinical studies indicate that botuli
num toxin (BTA) may prevent the formation of keloid and treat it, so the aim of this research was to compare the effectiveness of topical injection of botulinum toxin versus topical steroid injection in the treatment of keloid. Methods: The research sample included 23 patients from the dermatology clinic at Tishreen University Hospital in Lattakia between 2019 and 2020, with keloids. The number of keloids registered with the studied sample was 30 distributed to two groups: Group A receiving IL steroid repeated every 4 weeks for six sessions, Group B IL BTA 5 IU /cm3 repeated every 8 weeks for three sessions. Objective parameters (hardness, elevation, pigmentation and vasscularity), subjective complaints (itching, pain, and tenderness), patient satisfaction, and side effects were evaluated. Results: There was a 58.4% decrease in the Vancouver scale for group A, and 65.8% for group B, without a statistical difference between the two groups (P <0.05). A noticeable decrease in tenderness 85.9% in treatment group A and 82.7% in treatment group B. A significant decrease in elevation in A 79.4% while B had a slight decrease of 27%. For vascularity we observed a slight decrease in treatment group A of 17.7% without statistical significance, whereas in treatment group B there was a decrease of 58%. The itching improvement in treatment group B was shown to be greater with statistically significant differences (P<0.05). Skin atrophy and telangiectasia were evident in 11 patients of group A. Conclusions: This study showed the efficacy and safety of topical toxin injection in treating keloid by improving objective and subjective criteria when compared to topical injection of corticosteroids. With fewer side effects reported for botulinum toxin.
Log in to be able to interact and post comments
comments
Fetching comments
Sign in to be able to follow your search criteria
